Low-molecular-weight heparin treatment failure in prevention of prosthetic mitral valve thrombosis.
David Šuran, Vojko Kanič, Tatjana Golob Gulič, Franjo Husam Naji, Robert Lipovec · Slovenian Medical Journal · 2009
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Slovenian Medical Journal · Slovenian Medical Association · article · 2009
Abstract
Background Prosthetic heart valve thrombosis (PHVT) represents a dangerous postoperative complication following prosthetic heart valve replacement. Incidence varies according to different data from 0.5–4 % per year following mitral or aortic valve replacement in spite of adequate oral anticoagulation with coumarins. Case report We are presenting a case of prosthetic mitral valve thrombosis as a result of 6-month lowmolecular-weight heparin (LMWH) (nadroparine) treatment failure. Our patient presented with clinical picture of massive and recurrent bilateral pleural effusions and sub sequent development of acute left-sided heart failure.
Diagnosis was made with transesophageal ultrasound examination. The patient underwent surgical thrombectomy and recovered completely. He died a month later because of pneumonia with septic complications and multiorgan failure. Conclusions Our case raises suspicion that the use of LMWHs as an alternative anticoagulant for long-term antithrombotic prophylaxis in patients with prosthetic heart valves carries an increased risk of PHVT. There is a lack of larger randomised trials comparing the safety of LMWH and coumarin anticoagulation in patients with prosthetic heart valves.
Open the resolved locator · 10.6016/371
Metadata licence: OpenAlex metadata (CC0)